Apimeds Pharmaceuticals US, Inc.
APUS evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $3.2M
- Lead Asset:
- apitox (Preclinical)
What it means
What to watch
Prepared research question
What matters most for APUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APUS
Apimeds Pharmaceuticals US, Inc. (APUS) is a biopharmaceutical company developing APITOX, a bee-venom-based biologic candidate for multiple sclerosis and osteoarthritis pain, currently in preclinical and regulatory stages.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$3.2M
Cash Runway
—
Lead Asset
apitox (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Apimeds Pharmaceuticals US, Inc..
Apimeds Pharmaceuticals US, Inc. (APUS) is a biopharmaceutical company developing APITOX, a bee-venom-based biologic candidate for multiple sclerosis and osteoarthritis pain, currently in preclinical and regulatory stages.
- Cash & equivalents of $0.3M as of 2026-06-30 [sec]
- Net income of -$20.2M as of 2026-06-30 [sec]
- Shareholders' equity of $106.4M as of 2026-06-30 [sec]
- Lead program APITOX is in preclinical development for Multiple Sclerosis (MS) [pipeline]
- Settled disputes with Inscobee in May 2026, clearing path for $100M PIPE financing and merger completion [news · published 2026-05-05]
What works
- Settlement with Inscobee resolved outstanding disputes, enabling merger completion and $100M PIPE financing [news · published 2026-05-05]
- FDA Type C meeting confirmed for May 2026 to discuss APITOX (LT-100) for osteoarthritis pain, indicating regulatory engagement [news · published 2026-02-11]
- Appointment of Dr. Christopher Kim as Chief Scientific Officer brings deep expertise in APITOX program [news · published 2026-08-06]
What to weigh
- Cash position is very low at $0.3M as of 2026-06-30, suggesting limited operating runway without additional financing [sec]
- Net loss of -$20.2M as of 2026-06-30 reflects significant ongoing expenses relative to revenue [sec]
- APITOX for MS remains in preclinical phase, with no clinical data yet, while competitors have advanced Phase 2/3 trials in MS [pipeline][competitor_trial]
Risks & what to watch (3)›
Key risks
- Low cash runway — Cash of $0.3M as of 2026-06-30 may be insufficient to sustain operations without near-term financing [sec]
- Preclinical stage for MS — APITOX for MS is preclinical; competitors have Phase 2/3 trials, raising development risk [pipeline][competitor_trial]
- Net loss trend — Net loss of -$20.2M as of 2026-06-30 indicates high cash burn relative to revenue [sec]
What to watch
- Completion of $100M PIPE financing and its impact on cash runway [news · published 2026-05-05]
- Outcome of FDA Type C meeting for APITOX (LT-100) for osteoarthritis pain, held May 4, 2026 [news · published 2026-02-11]
- Progress of APITOX from preclinical to clinical development for MS [pipeline]
Sources: Competitor trials · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run Apimeds Pharmaceuticals US, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apimeds Pharmaceuticals US, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.20 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 1.7%
- Days to cover
- 21.1
- Shares short
- 92,972
- Daily short volume (Jul 6, 2026)
- 46.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APUS short interestFrequently asked questions
What is the AI investment thesis for Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. (APUS) is a biopharmaceutical company developing APITOX, a bee-venom-based biologic candidate for multiple sclerosis and osteoarthritis pain, currently in preclinical and regulatory stages.
What is Apimeds Pharmaceuticals US, Inc.'s lead drug candidate?
Apimeds Pharmaceuticals US, Inc.'s most advanced tracked candidate is apitox (Preclinical) for Multiple Sclerosis (MS).
Who is the CEO of Apimeds Pharmaceuticals US, Inc.?
Dr. Vinod Menon is the chief executive officer of Apimeds Pharmaceuticals US, Inc. (APUS).
Where is Apimeds Pharmaceuticals US, Inc. headquartered?
Apimeds Pharmaceuticals US, Inc. (APUS) is headquartered in Matawan, NJ, United States.
What therapeutic areas does Apimeds Pharmaceuticals US, Inc. focus on?
Apimeds Pharmaceuticals US, Inc. develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.